Loading…
Lobbying Spend
—
Filings
150
Firms Hired
4
Active Period
2005–2022
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Cancer Patient Protection Act of 2013
2016 · second_quarter · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Client expense: — · Firm income: $20,000
Matched citations: HR 1416
Cancer Patient Protection Act of 2013
2016 · second_quarter · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Client expense: — · Firm income: $20,000
Matched citations: HR 1416
Safeguarding America's Pharmaceuticals Act of 2013
2016 · second_quarter · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Client expense: — · Firm income: $20,000
Matched citations: HR 1919
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Client expense: — · Firm income: $20,000
Matched citations: HR 3204
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Client expense: — · Firm income: $20,000
Matched citations: HR 800
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Client expense: — · Firm income: $20,000
Matched citations: HR 800
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Client expense: — · Firm income: $20,000
Matched citations: S. 957
Pharmaceutical Quality, Security, and Accountability Act
2016 · second_quarter · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Client expense: — · Firm income: $20,000
Matched citations: S. 959
Drug Free Commercial Driver Act of 2015
2016 · second_quarter · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Client expense: — · Firm income: $20,000
Matched citations: S. 806
Drug Free Commercial Driver Act of 2015
2016 · second_quarter · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Client expense: — · Firm income: $20,000
Matched citations: S. 806
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
2016 · fourth_quarter · Firm: DENTONS US LLP
Implementation of the Patient Protection and Affordable Care Act; issues related to Medicare drug reimbursement; H.R. 696; S. 506
Client expense: — · Firm income: $30,000
Matched citations: H.R. 696
North American Energy Security and Infrastructure Act of 2015
2016 · fourth_quarter · Firm: DENTONS US LLP
LIFO tax issues; corporate rate reform, H.R. 8
Client expense: — · Firm income: $30,000
Matched citations: H.R. 8
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
2016 · fourth_quarter · Firm: DENTONS US LLP
Implementation of the Patient Protection and Affordable Care Act; issues related to Medicare drug reimbursement; H.R. 696; S. 506
Client expense: — · Firm income: $30,000
Matched citations: S. 506
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
2016 · third_quarter · Firm: DENTONS US LLP
Implementation of the Patient Protection and Affordable Care Act; issues related to Medicare drug reimbursement; H.R. 696; S. 506
Client expense: — · Firm income: $30,000
Matched citations: H.R. 696
North American Energy Security and Infrastructure Act of 2015
2016 · third_quarter · Firm: DENTONS US LLP
LIFO tax issues; corporate rate reform, H.R. 8
Client expense: — · Firm income: $30,000
Matched citations: H.R. 8
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
2016 · third_quarter · Firm: DENTONS US LLP
Implementation of the Patient Protection and Affordable Care Act; issues related to Medicare drug reimbursement; H.R. 696; S. 506
Client expense: — · Firm income: $30,000
Matched citations: S. 506
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
2016 · second_quarter · Firm: DENTONS US LLP
Implementation of the Patient Protection and Affordable Care Act; issues related to Medicare drug reimbursement; H.R. 696; S. 506
Client expense: — · Firm income: $40,000
Matched citations: H.R. 696
North American Energy Security and Infrastructure Act of 2015
2016 · second_quarter · Firm: DENTONS US LLP
LIFO tax issues; corporate rate reform, H.R. 8
Client expense: — · Firm income: $40,000
Matched citations: H.R. 8
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
2016 · second_quarter · Firm: DENTONS US LLP
Implementation of the Patient Protection and Affordable Care Act; issues related to Medicare drug reimbursement; H.R. 696; S. 506
Client expense: — · Firm income: $40,000
Matched citations: S. 506
Cancer Patient Protection Act of 2013
2016 · first_quarter · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Client expense: — · Firm income: $20,000
Matched citations: HR 1416
Cancer Patient Protection Act of 2013
2016 · first_quarter · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Client expense: — · Firm income: $20,000
Matched citations: HR 1416
Safeguarding America's Pharmaceuticals Act of 2013
2016 · first_quarter · Firm: THE WALTER GROUP
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Client expense: — · Firm income: $20,000
Matched citations: HR 1919
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Client expense: — · Firm income: $20,000
Matched citations: HR 3204
HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.
Client expense: — · Firm income: $20,000
Matched citations: HR 800
HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.
Client expense: — · Firm income: $20,000
Matched citations: HR 800
Source: Senate LDA